Archive · 13 Jun 2025
AstraZeneca and CSPC Partner for AI-Driven Chronic Disease Research
Imagine two big companies, AstraZeneca and CSPC, joining forces to fight diseases that last a long time, like diabetes.
They're using smart computer programs called AI to help find new medicines.
AstraZeneca will pay CSPC a lot of money, up to $5.3 billion!
CSPC will do the research in China, using its special AI tools.
AstraZeneca can then take these new medicines and sell them worldwide.
This is a big step to help people with these diseases.
AstraZeneca and CSPC Pharmaceuticals are partnering on AI research for chronic diseases.
The deal is worth up to $5.3 billion, including upfront and milestone payments.
CSPC will utilize its AI-driven drug discovery platform in Shijiazhuang.
AstraZeneca will receive exclusive licenses for candidates identified under the deal.
The collaboration aims to address chronic diseases impacting billions globally.
- Who
- AstraZeneca and CSPC Pharmaceuticals are the primary entities involved.
- What
- AstraZeneca and CSPC Pharmaceuticals are collaborating on AI-assisted research to tackle chronic diseases.
- When
- The partnership was announced on Friday.
- Where
- CSPC will conduct research in Shijiazhuang, China.
- Why
- To develop new treatments for chronic diseases.
- Partners
- AstraZeneca, CSPC Pharmaceuticals
- Deal Value
- Up to $5.3 billion
- Upfront Payment
- $110 million
- Location of Research
- Shijiazhuang, China
- Focus
- Chronic diseases